Christopher J. de Bakker

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The development and production of recombinant DNA-derived biologic medicines (also commonly referred to as ‘biologics’ or ‘biopharmaceuticals’) make them highly individual products. The original biologic developed by the innovator is termed the innovator product, and has market exclusivity for the lifetime of the patent. Biologics which are similar but not(More)
  • Christopher B Howard, Nicholas Fletcher, +9 authors Kristofer J Thurecht
  • Advanced healthcare materials
  • 2016
Targeted nanomaterials promise improved therapeutic efficacy, however their application in nanomedicine is limited due to complexities associated with protein conjugations to synthetic nanocarriers. A facile method to generate actively targeted nanomaterials is developed and exemplified using polyethylene glycol (PEG)-functional nanostructures coupled to a(More)
Human Chaperonin 10 (hCpn10) was utilised as a novel scaffold for presenting peptides of therapeutic and diagnostic significance. Molecular dynamic simulations and protein sizing analyses identified a peptide linker (P1) optimal for the formation of the quarternary hCpn10 heptamer structure. hCpn10 scaffold displaying peptides targeting Factor VIIa(More)
  • 1